Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.66 |
| ▸ | HPGD | P15428 | 5/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.66 |
| ▸ | HTT | P42858 | 4/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | BRD4 | O60885 | 1/20 | 0.66 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.57 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Irloxacin SCHEMBL9743690 | 0.99 | DRD3 (0.66) | DRD3KDM4EHPGDALDH1A1HSD17B10 | |
| Irloxacin SCHEMBL9743701 | 0.99 | DRD3 (0.66) | DRD3KDM4EHPGDALDH1A1HSD17B10 | |
| SCHEMBL10671111 | 0.91 | ALDH1A1 (0.59) | DRD3KDM4EHPGDALDH1A1HSD17B10 | |
| SCHEMBL16518634 | 0.89 | DRD3 (0.54) | DRD3KDM4EHPGDALDH1A1HSD17B10 | |
| Irloxacin SCHEMBL9743694 | 0.88 | DRD3 (0.53) | DRD3KDM4EHPGDALDH1A1HSD17B10 | |
| SCHEMBL10372171 | 0.88 | ALDH1A1 (0.67) | DRD3KDM4EHPGDALDH1A1HSD17B10 | |
| SCHEMBL9757197 | 0.87 | DRD3 (0.64) | DRD3KDM4EHPGDALDH1A1HSD17B10 | |
| SCHEMBL10369898 | 0.87 | ALDH1A1 (0.57) | DRD3KDM4EHPGDALDH1A1HSD17B10 | |
| SCHEMBL10972617 | 0.86 | KDM4E (0.68) | DRD3KDM4EHPGDALDH1A1HSD17B10 | |
| SCHEMBL9700859 | 0.85 | DRD3 (0.61) | DRD3KDM4EHPGDALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118354776-A | Methods and compositions for enhanced efficacy and reduced toxicity of non-implanted CD8 depleted allogeneic donor lymphocyte infusions | 约翰霍普金斯大学 | 2024-07-16 | — | — | CN | claimed |
| US-20230285572-A1 | TARGETED DELIVERY OF THERAPEUTIC AGENTS | SEPELO THERAPEUTICS, LLC | 2023-09-14 | — | — | US | claimed |
| EP-4188433-A2 | TARGETED DELIVERY OF THERAPEUTIC AGENTS | Sepelo Therapeutics, LLC (US) | 2023-06-07 | — | — | EP | claimed |
| WO-2023028364-A1 | TARGETED COMPOSITIONS AND USES THEROF | SEPELO THERAPEUTICS, LLC (US) | 2023-03-02 | — | — | WO | claimed |
| WO-2022031761-A2 | TARGETED DELIVERY OF THERAPEUTIC AGENTS | SEPELO THERAPEUTICS, LLC (US) | 2022-02-10 | — | — | WO | claimed |
| US-10953073-B2 | XTEN conjugate compositions and methods of making same | AMUNIX PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | claimed |
| CN-111135182-A | Antibacterial product and preparation method and application thereof | 心远(广州)药物研究有限公司 | 2020-05-12 | — | — | CN | claimed |
| CN-109847109-A | A kind of contact lens carrying medicine | 滕宇池 | 2019-06-07 | — | — | CN | claimed |
| US-20190099363-A1 | CHEMICALLY MODIFIED SMALL MOLECULES | REDHILL BIOPHARMA LTD. (IL) | 2019-04-04 | — | — | US | claimed |
| CN-104725628-B | A kind of single functionalization branched polyethylene glycol, preparation method and its bio-related substance containing degradable group | 厦门赛诺邦格生物科技股份有限公司 | 2018-04-17 | — | — | CN | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| CN-1500488-A | Oral colon-positioned medicine composition for curing bacillary dysentery | 北京东方凯恩医药科技有限公司 | 2004-06-02 | — | — | CN | claimed |
| US-4895803-A | QUINOLINE-OR NAPHTHAPYRIDINE/1,8-/ DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 1990-01-23 | — | — | US | claimed |
| US-4853225-A | Process for implanting a medicament depot | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1989-08-01 | — | — | US | claimed |
| US-4844902-A | Topically applicable formulations of gyrase inhibitors in combination with corticosteroids | BAYER AKTIENGESELLSCHAFT (DE) | 1989-07-04 | — | — | US | claimed |
| EP-0280915-A2 | Preparations for topical use of gyrase inhibitors in combination with corticosteroids | BAYER AG (DE) | 1988-09-07 | — | — | EP | claimed |
| EP-0134165-B1 | 7-(PYRROL-1-YL)-1-ETHYL-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXYLIC ACID AND 7-(PYRROL-1-YL)-1-ETHYL-1,4-DIHYDRO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | PROVESAN S.A. (CH) | 1988-06-08 | — | — | EP | claimed |
| US-4552882-A | 7-(1-Pyrrolyl) derivatives of 1-ethyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids and 1-ethyl-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids and their use as antimicrobial agents | PROVESAN, SA (CH) | 1985-11-12 | — | — | US | claimed |
| EP-0155244-A2 | 1-Ethyl-6-fluoro-7-(1H-pirrol-1-yl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid: preparation and antimicrobial activities | BIOCHEM DESIGN S.r.l. (IT) | 1985-09-18 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10953073-B2 | XTEN conjugate compositions and methods of making same | XPA, TXLNA, NGLY1 | DRD3 2834/4885KDM4E 2338/4885HPGD 2116/4885 |
| US-20190099363-A1 | CHEMICALLY MODIFIED SMALL MOLECULES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CD44, ELANE | DRD3 2250/4885KDM4E 2294/4885HPGD 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.